Month: September 2025
-
Combination Therapies in Pharma – Removing the Antitrust Roadblock
This month, the Belgian Competition Authority (BCA) published guidance on information exchange between pharmaceutical companies in the context of the reimbursement application procedure for combination therapies. This follows a prioritisation statement adopted by the UK Competition and Markets Authority (CMA) in 2023 on the same issue and long-standing demands from the Belgian pharmaceutical industry.[1] In…
-
Private Equity and Common Ownership in Professional Rugby: Applying the Delivery Hero Standard
By Dr Beverley Williamson From time to time, the Thicket blog invites guest bloggers to write about a topic that is close to their heart. Geradin Partners is pleased to give the floor to friend of the blog Dr Bev Williamson who is an expert in the application of competition law in the sports industry.…
-
Nissan Iberia (C-21/24): The Clock for Damages Actions Only Starts Ticking Once the National Competition Authority’s Decision is Final
Introduction Private damages actions are now firmly established as a key tool of EU competition law enforcement. As regularly asserted by the Court of Justice of the European Union (“CJEU” or the “Court”), damages actions are not only about compensating victims of antitrust infringements, but also about deterring anticompetitive conduct to preserve effective competition in…